Updated on 31 October 2013
Sanofi's other designated growth areas--consumer healthcare and Genzyme among them also pumped things up. The launch of multiple sclerosis drug Aubagio, coupled with rare-disease growth, lifted Genzyme sales by 21 percent to $727.6 million.
The CEO assured that the emerging markets won't continue to be a drag. "In China, for instance, new hospitals are popping up regularly, adding new customers each time," he said. The company intends to continue investing there, and in other countries, if on a more targeted, thoughtful basis, he added.
"There will be some ups and downs. You're going to have currency movements, there are going to be some issues on pricing, but you are going to still see a volume increase. Here and there will be pockets of slowdown, but there's still growth to be found. We may just have to look harder for it.," he reportedly told analysts in a conference call.